| Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination D Firinu, A Perra, M Campagna, R Littera, G Fenu, F Meloni, S Cipri, ... Clinical and experimental medicine 22 (3), 477-485, 2022 | 20 | 2022 |
| Evaluation of antibody response to heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2: an observational study D Firinu, A Perra, M Campagna, R Littera, F Meloni, F Sedda, M Conti, ... Vaccines 9 (12), 1478, 2021 | 9 | 2021 |
| A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G S Mocci, R Littera, L Chessa, M Campagna, M Melis, CM Ottelio, IS Piras, ... Frontiers in Immunology 14, 1138559, 2023 | 7 | 2023 |
| Potential use of TG68-A novel thyromimetic-for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis A Caddeo, M Serra, F Sedda, A Bacci, C Manera, S Rapposelli, ... Frontiers in Oncology 13, 1127517, 2023 | 6 | 2023 |
